Discovery and commercialisation of novel compounds targeting redox proteins
The Peroxiredoxin proteins represent a currently untapped molecular therapeutic target. We recently characterised a range
of novel chemical compounds that could alter the function of one of the peroxiredoxin family members, peroxi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto REDOXDRUGS
Duración del proyecto: 17 meses
Fecha Inicio: 2016-08-30
Fecha Fin: 2018-02-28
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The Peroxiredoxin proteins represent a currently untapped molecular therapeutic target. We recently characterised a range
of novel chemical compounds that could alter the function of one of the peroxiredoxin family members, peroxiredoxin 4
(PRDX4). The approach involved high-throughput computational virtual compound screening involving our supercomputer
facility at the University of Cambridge. Given our success in finding chemicals that could affect the function of these
proteins, we would now like to screen and provide proof-of-principle evidence of the efficacy of novel compounds for further
development as therapeutic agents.
This process has been very rapid for prototyping novel molecules, from idea to hit compound validation in biological assays
in less than 6 months. This rapid development cycle is highly cost-efficient and produces a range of chemical hits that
could subsequently be taken forward as lead compounds for pre-clinical and clinical studies in the future, as novel
therapeutics for a range of diseases ranging from cardiovascular and metabolic disease to cancer.